Strides' New CEO Reiterates Strategy, Thrust On Execution

Q3 Revenues Up 29% Led By US, UK

Newly-appointed CEO at Strides, R Ananthanarayanan, sees no reason to change course as current strategy continues yielding positive results. Company posts 29% increase in third-quarter revenues on the back of 62% growth in the US

Business success growing growth increase up concept. Wooded cube block on white background with word GROWTH
Strides Pharma Posts Impressive Growth • Source: Shutterstock

A new CEO is often under close observation for indications of a shift in strategic direction. At Strides Pharma Science Ltd, earlier known as Strides Shasun Ltd., R Ananthanarayanan, appointed CEO a little over a fortnight ago, doesn’t see reason to rock the boat, at least for now.

On a 30 January investor call detailing third-quarter results for FY20, as former CEO and current chairman Arun Kumar introduced...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip